# Clinical Trial of Efficacy and Safety of MMH-MAP in the Treatment of Mild Cognitive Impairment in Early Recovery Stage After Ischemic Stroke

> **NCT03815292** · PHASE3 · COMPLETED · sponsor: **Materia Medica Holding** · enrollment: 276 (actual)

## Conditions studied

- Mild Cognitive Impairment
- Ischemic Stroke

## Interventions

- **DRUG:** MMH-MAP
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03815292
- **Lead sponsor:** Materia Medica Holding
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-19
- **Primary completion:** 2020-01-27
- **Final completion:** 2020-01-27
- **Target enrollment:** 276 (ACTUAL)
- **Last updated:** 2021-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03815292

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03815292, "Clinical Trial of Efficacy and Safety of MMH-MAP in the Treatment of Mild Cognitive Impairment in Early Recovery Stage After Ischemic Stroke". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT03815292. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*